Perspective Therapeutics, Inc.
CATX
$1.94
$0.094.87%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.39% | 351.13% | 78.32% | -44.27% | -73.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.39% | 351.13% | 78.32% | -44.27% | -73.52% |
| Cost of Revenue | 93.82% | 1,661.24% | -- | 1,188.35% | 567.42% |
| Gross Profit | -99.59% | -2,850.51% | -2,399.51% | -1,723.55% | -898.86% |
| SG&A Expenses | 26.34% | 36.63% | 26.11% | 47.52% | 125.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 200.00% | 200.00% | -- | -- |
| Total Operating Expenses | 61.06% | 98.97% | 95.79% | 129.83% | 198.14% |
| Operating Income | -63.15% | -89.78% | -96.36% | -157.60% | -365.34% |
| Income Before Tax | -100.54% | -69.29% | -85.02% | -157.05% | -372.67% |
| Income Tax Expenses | 20.90% | 174.75% | 174.75% | 174.75% | -- |
| Earnings from Continuing Operations | -109.13% | -204.47% | -287.79% | -733.58% | -341.43% |
| Earnings from Discontinued Operations | 89.52% | -56.93% | -122.20% | -448.98% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.46% | -154.12% | -213.73% | -497.11% | -332.23% |
| EBIT | -63.15% | -89.78% | -96.36% | -157.60% | -365.34% |
| EBITDA | -111.92% | -88.77% | -95.39% | -157.53% | -371.34% |
| EPS Basic | 27.43% | -49.85% | -79.88% | -178.83% | -119.27% |
| Normalized Basic EPS | 41.69% | 8.95% | -7.37% | -49.67% | -161.46% |
| EPS Diluted | -6.96% | -49.85% | -79.88% | -178.83% | -119.27% |
| Normalized Diluted EPS | 41.69% | 8.95% | -7.37% | -49.67% | -161.46% |
| Average Basic Shares Outstanding | 140.75% | 130.75% | 117.35% | 104.12% | 88.31% |
| Average Diluted Shares Outstanding | 140.75% | 130.75% | 117.35% | 104.12% | 88.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |